Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity.

Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity.

Item
http://www.wikidata.org/entity/Q50962057
Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET ImagingExploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisNeural Plasticity in Multiple Sclerosis: The Functional and Molecular BackgroundBiomarkers of therapeutic response in multiple sclerosis: current statusMultiple sclerosis masquerading as Alzheimer-type dementia: Clinical, radiological and pathological findings.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.Amyloid-β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis.Fluid biomarker and electrophysiological outcome measures for progressive MS trials.Recent advances in phosphoproteomics and application to neurological diseases.Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis.Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis.Science is 1% inspiration and 99% biomarkers.
P2860

Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity.

Item
http://www.wikidata.org/entity/Q50962057
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Evaluating biomarkers of neuro ...... l marker of clinical severity.
@en
Evaluating biomarkers of neuro ...... l marker of clinical severity.
@nl
type
label
Evaluating biomarkers of neuro ...... l marker of clinical severity.
@en
Evaluating biomarkers of neuro ...... l marker of clinical severity.
@nl
prefLabel
Evaluating biomarkers of neuro ...... l marker of clinical severity.
@en
Evaluating biomarkers of neuro ...... l marker of clinical severity.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Evaluating biomarkers of neuro ...... al marker of clinical severity
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921